SUPPLEMENT

Q1 2022 — Reconciliation of Non-GAAP Financial Measures

Q1 2022PDF · 4 pages305 KB
Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Dollars in Millions Except Per Share Data) 2022 2021
Net Earnings, after tax- as reported $5,149 $6,197
Pre-tax Adjustments
Intangible Asset Amortization expense 1,108 1,215
IPR&D 610 -
Restructuring related 72 104
Acquisition, integration and divestiture related ¹ - (538)
(Gains)/losses on securities 411 35
Medical Device Regulation 2 60 46
Consumer Health separation costs 102 -
Other (7) -
Tax Adjustments
Tax impact on special item adjustments 3 (393) (113)
Consumer Health separation tax related costs 96 -
Tax legislation and other tax related (79) (22)
Adjusted Net Earnings, after tax $7,129 $6,924
Average shares outstanding (Diluted) 2,666.5 2,672.7
Adjusted net earnings per share (Diluted) $2.67 $2.59
Operational adjusted net earnings per share (Diluted) $2.75
Notes:
1
2
3
First Quarter
Acquisition, integration and divestiture related for the first quarter of 2021 primarily includes the gain on the divestiture of 2
Pharmaceutical brands outside of the U.S.
The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-
tax special items in arriving at adjusted earnings.
European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered
products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of
currently marketed medical devices were required to comply with EU MDR beginning in May 2021. The Company considers the
adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company
has excluded only external third-party regulatory and consulting costs from its MedTech operating segments' measures of profit
and loss used for making operating decisions and assessing performance which is expected to be completed by the end of 2023.

-- 1 of 4 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Consumer Health Pharmaceutical MedTech Total
WW As Reported (1.5)% 6.3% 5.9% 5.0%
U.S. (3.4)% 2.9% 5.6% 2.7%
International 0.0% 10.3% 6.3% 7.2%
WW Currency (2.3) (3.0) (2.6) (2.7)
U.S. - - - -
International (4.1) (6.4) (4.8) (5.4)
WW Operational 0.8% 9.3% 8.5% 7.7%
U.S. (3.4)% 2.9% 5.6% 2.7%
International 4.1% 16.7% 11.1% 12.6%
Skin Health / Beauty
Dr. Ci Labo - Sedona 0.6 0.1
U.S. 0.0 0.0
International 1.1 0.2
All Other Acquisitions and Divestitures 0.2 0.0 0.1 0.1
U.S. 0.2 0.0 0.1 0.1
International 0.1 0.0 0.1 0.1
WW Adjusted Operational 1.6% 9.3% 8.6% 7.9%
U.S. (3.2)% 2.9% 5.7% 2.8%
International 5.3% 16.7% 11.2% 12.9%
Adjusted Operational Sales Growth
FIRST QUARTER 2022 ACTUAL vs. 2021 ACTUAL
Segments
Note: Percentages are based on actual, non-rounded figures and may not sum.

-- 2 of 4 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
2022 2021 2022 2021 2022 2021 2022 2021 2022 2021 2022 2021
Reported Income Before Tax by Segment $ 686 842 3,924 5,169 1,477 1,629 (123) (211) (102) - 5,862 7,429
% to Sales 19.1% 23.1% 30.5% 42.7% 21.2% 24.8% -0.5% -0.9% -0.4% 0.0% 25.0% 33.3%
Intangible asset amortization expense 94 106 760 856 254 253 - - - - 1,108 1,215
In-process research and development - - 610 - - - - - - - 610 -
Loss/(gain) on securities - (2) 394 37 17 - - - - - 411 35
Restructuring related 14 28 (14) 20 72 56 - - - - 72 104
Acquisition, integration and divestiture related - - - (570) - 32 - - - - - (538)
Medical Device Regulation - - - - 60 46 - - - - 60 46
Consumer Health separation costs - - - - - - - - 102 - 102 -
Other - - - - - - (7) - - - (7) -
Adjusted Income Before Tax by Segment $ 794 974 5,674 5,512 1,880 2,016 (130) (211) - - 8,218 8,291
% to Sales 22.1% 26.8% 44.1% 45.5% 27.0% 30.6% -0.6% -0.9% 0.0% 0.0% 35.1% 37.1%
1 Prior year income before tax has been reclassified as Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes in
their respective regions
Q1 YTD - Income Before Tax by Segment
Dollars in Millions
Consumer Health
Separation Costs	Consumer Health1 Pharmaceutical1 MedTech Unallocated Worldwide Total

-- 3 of 4 --

First Quarter Acquistion, integration First Quarter
April 3, 2022
GAAP
Intangible asset
amortization
Litigation
expense, net
Restructuring
related
and divestiture
related (1)	
Medical Device
Regulation Other
April 3, 2022
Non-GAAP
Cost of products sold 7,598	$ (1,108) (16) (22) 6,452
Selling, marketing and admin expenses 5,938 (6) 5,932
Research and development expense 3,462 (32) 3,430
Other (Income) / Expense (102) - - 14 - (411) (102) 7 (594)
In-process research and development 610 (610) -
Restructuring 70 (70) -
Provision for taxes on income 713 168 (53) 138 12 - 96 11 23 (96) 79 (2) 1,089
Net Earnings 5,149 940 53 472 60 - 315 49 79 96 (79) (5) 7,129
First Quarter Acquistion, integration First Quarter
April 4, 2021
GAAP
Intangible asset
amortization
Litigation
expense, net
Restructuring
related
and divestiture
related (1)	
Medical Device
Regulation Other
April 4, 2021
Non-GAAP
Cost of products sold 7,063	$ (1,215) (27) (17) 5,804
Selling, marketing and admin expenses 5,432 (5) 5,427
Research and development expense 3,178 (24) 3,154
Other (Income) / Expense (882) - - (24) 538 (35) - (403)
Restructuring 53 (53) -
Provision for taxes on income 1,232 177 - 20 (101) 8 9 - - 22 - 1,367
Net Earnings 6,197 1,038 - 84 (437) 27 37 - - (22) - 6,924
(1) 2021 primarily includes gains on the divestiture of 2 Pharmaceutical brands outside of the United States.
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Consumer Health
separation tax
related costs
In-process
research and
development
(Loss)/gain on
securities
Consumer Health
separation costs
Tax legislation
and other tax
related
Consumer Health
separation tax
related costs
In-process
research and
development
(Loss)/gain on
securities
Consumer Health
separation costs
Tax legislation
and other tax
related

-- 4 of 4 --